Study questions precautionary measures on paternal use of valproate

A new study from researchers at Aarhus University and Aarhus University Hospital found no increased risk of neurodevelopmental disorders in children whose fathers were treated with valproate during spermatogenesis. The results have just been published in JAMA Network Open and cast new light on the European Medicines Agency’s (EMA’s) recent recommendation for precautionary measures.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup